| Year |
Citation |
Score |
| 2023 |
Alim E, Stone L, Sharma N, McMahon S, Allen Z, Aceto P, Victor P, Mitchell LF, Raulerson A, Schepke C, Grabowski J, Valera R, Kalia K, Fernandez M, Kouba K, ... ... Rhodes LV, et al. Single Live Cell Imaging of Multidrug Resistance Using Silver Ultrasmall Nanoparticles as Biosensing Probes in Triple-Negative Breast Cancer Cells. Acs Applied Bio Materials. PMID 37844294 DOI: 10.1021/acsabm.3c00451 |
0.487 |
|
| 2021 |
Burks HE, Matossian MD, Rhodes LV, Phamduy T, Elliott S, Buechlein A, Rusch DB, Miller DFB, Nephew KP, Chrisey D, Collins-Burow BM, Burow ME. ZEB2 regulates endocrine therapy sensitivity and metastasis in luminal a breast cancer cells through a non-canonical mechanism. Breast Cancer Research and Treatment. PMID 34231077 DOI: 10.1007/s10549-021-06256-x |
0.732 |
|
| 2021 |
Matossian MD, Elliott S, Rhodes LV, Martin EC, Hoang VT, Burks HE, Zuercher WJ, Drewry DH, Collins-Burow BM, Burow ME. Application of a small molecule inhibitor screen approach to identify CXCR4 downstream signaling pathways that promote a mesenchymal and fulvestrant-resistant phenotype in breast cancer cells. Oncology Letters. 21: 380. PMID 33777204 DOI: 10.3892/ol.2021.12641 |
0.61 |
|
| 2019 |
Horgan XJ, Tatum H, Brannan E, Paull DH, Rhodes LV. Resveratrol analogues surprisingly effective against triple‑negative breast cancer, independent of ERα. Oncology Reports. PMID 31002359 DOI: 10.3892/Or.2019.7122 |
0.643 |
|
| 2019 |
Matossian MD, Burks HE, Elliott S, Hoang VT, Bowles AC, Sabol RA, Wahba B, Anbalagan M, Rowan B, Abazeed ME, Bunnell BA, Moroz K, Miele L, Rhodes LV, Jones SD, et al. Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model. Bmc Cancer. 19: 205. PMID 30845999 DOI: 10.1186/S12885-019-5401-2 |
0.683 |
|
| 2019 |
Byrne C, Martin E, Melvin A, Rahman S, King C, Copeland C, Rhodes L, Glotser E, Skripnikova E, Wiese T, Bratton M. SAT-LB055 Using Fluidics to Model the Genomic Evolution of Metastatic Breast Cancer Journal of the Endocrine Society. 3. DOI: 10.1210/js.2019-sat-lb055 |
0.432 |
|
| 2018 |
Matossian MD, Burks HE, Bowles AC, Elliott S, Hoang VT, Sabol RA, Pashos NC, O'Donnell B, Miller KS, Wahba BM, Bunnell BA, Moroz K, Zea AH, Jones SD, Ochoa AC, ... ... Rhodes LV, et al. A novel patient-derived xenograft model for claudin-low triple-negative breast cancer. Breast Cancer Research and Treatment. PMID 29392581 DOI: 10.1007/S10549-018-4685-2 |
0.703 |
|
| 2016 |
Conger AK, Martin EC, Yan TJ, Rhodes LV, Hoang VT, La J, Anbalagan M, Burks HE, Rowan BG, Nephew KP, Collins-Burow BM, Burow ME. Argonaute 2 Expression Correlates with a Luminal B Breast Cancer Subtype and Induces Estrogen Receptor Alpha Isoform Variation. Non-Coding Rna. 2. PMID 29657266 DOI: 10.3390/Ncrna2030008 |
0.742 |
|
| 2016 |
Burks HE, Rhodes LV, Martin EC, Hoang VT, Elliott S, Badoo M, Phamduy T, Buechlein A, Rusch D, Chrisey D, Flemington E, Nephew K, Collins-Burow B, Burow ME. Abstract 4410: ZEB2 drives cell motility and metastasis in ER+ breast cancer cells through a novel, E-cadherin independent pathway Cancer Research. 76: 4410-4410. DOI: 10.1158/1538-7445.Am2016-4410 |
0.764 |
|
| 2016 |
Robert E, Rhodes LV. Abstract 3318: Exploring the utility of natural and synthetic resveratrol derivatives for bone regrowth following loss due to breast cancer therapies Cancer Research. 76: 3318-3318. DOI: 10.1158/1538-7445.Am2016-3318 |
0.515 |
|
| 2016 |
Hoang VT, Elliott S, Martin EC, Rhodes LV, Burks HE, Matossian M, Chakrabarty S, Monlish D, Phamduy TB, Curley L, Anbalagan M, Rowan BG, Chrisey D, Cavanaugh JE, Flaherty PT, et al. Abstract 1596: Induction of mesenchymal-to-epithelial transition through pan-MEK inhibition in triple-negative breast cancer Cancer Research. 76: 1596-1596. DOI: 10.1158/1538-7445.Am2016-1596 |
0.745 |
|
| 2015 |
Rhodes LV, Tate CR, Hoang VT, Burks HE, Gilliam D, Martin EC, Elliott S, Miller DB, Buechlein A, Rusch D, Tang H, Nephew KP, Burow ME, Collins-Burow BM. Regulation of triple-negative breast cancer cell metastasis by the tumor-suppressor liver kinase B1. Oncogenesis. 4: e168. PMID 26436950 DOI: 10.1038/oncsis.2015.27 |
0.741 |
|
| 2015 |
Strong AL, Ohlstein JF, Biagas BA, Rhodes LV, Pei DT, Tucker HA, Llamas C, Bowles AC, Dutreil MF, Zhang S, Gimble JM, Burow ME, Bunnell BA. Leptin produced by obese adipose stromal/stem cells enhances proliferation and metastasis of estrogen receptor positive breast cancers. Breast Cancer Research : Bcr. 17: 112. PMID 26286584 DOI: 10.1186/S13058-015-0622-Z |
0.669 |
|
| 2015 |
Rhodes LV, Martin EC, Segar HC, Miller DF, Buechlein A, Rusch DB, Nephew KP, Burow ME, Collins-Burow BM. Dual regulation by microRNA-200b-3p and microRNA-200b-5p in the inhibition of epithelial-to-mesenchymal transition in triple-negative breast cancer. Oncotarget. 6: 16638-52. PMID 26062653 DOI: 10.18632/Oncotarget.3184 |
0.621 |
|
| 2015 |
Bratton MR, Martin EC, Elliott S, Rhodes LV, Collins-Burow BM, McLachlan JA, Wiese TE, Boue SM, Burow ME. Glyceollin, a novel regulator of mTOR/p70S6 in estrogen receptor positive breast cancer. The Journal of Steroid Biochemistry and Molecular Biology. 150: 17-23. PMID 25771071 DOI: 10.1016/J.Jsbmb.2014.12.014 |
0.719 |
|
| 2014 |
Zhuang Y, Nguyen HT, Burow ME, Zhuo Y, El-Dahr SS, Yao X, Cao S, Flemington EK, Nephew KP, Fang F, Collins-Burow B, Rhodes LV, Yu Q, Jayawickramarajah J, Shan B. Elevated expression of long intergenic non-coding RNA HOTAIR in a basal-like variant of MCF-7 breast cancer cells. Molecular Carcinogenesis. PMID 25328122 DOI: 10.1002/Mc.22237 |
0.722 |
|
| 2014 |
Martin EC, Rhodes LV, Elliott S, Krebs AE, Nephew KP, Flemington EK, Collins-Burow BM, Burow ME. microRNA regulation of mammalian target of rapamycin expression and activity controls estrogen receptor function and RAD001 sensitivity. Molecular Cancer. 13: 229. PMID 25283550 DOI: 10.1186/1476-4598-13-229 |
0.681 |
|
| 2014 |
Rhodes LV, Tate CR, Segar HC, Burks HE, Phamduy TB, Hoang V, Elliott S, Gilliam D, Pounder FN, Anbalagan M, Chrisey DB, Rowan BG, Burow ME, Collins-Burow BM. Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators. Breast Cancer Research and Treatment. 145: 593-604. PMID 24810497 DOI: 10.1007/S10549-014-2979-6 |
0.742 |
|
| 2014 |
Martin EC, Elliott S, Rhodes LV, Antoon JW, Fewell C, Zhu Y, Driver JL, Jodari-Karimi M, Taylor CW, Flemington EK, Beckman BS, Collins-Burow BM, Burow ME. Preferential star strand biogenesis of pre-miR-24-2 targets PKC-alpha and suppresses cell survival in MCF-7 breast cancer cells. Molecular Carcinogenesis. 53: 38-48. PMID 22911661 DOI: 10.1002/Mc.21946 |
0.615 |
|
| 2014 |
Rhodes LV, Tate CR, Burks HE, Hoang VT, Gilliam D, Martin EC, Elliott S, Miller DF, Buechlein A, Rusch D, Tang H, Nephew KP, Burow ME, Collins-Burow BM. Abstract 1571: The tumor suppressor Liver Kinase B1 inhibits triple-negative breast cancer cell metastasis via regulation of AP-1 signaling Cancer Research. 74: 1571-1571. DOI: 10.1158/1538-7445.Am2014-1571 |
0.765 |
|
| 2014 |
Hoang VT, Elliott S, Martin EC, Rhodes LV, Segar HC, Burks H, Chakrabarty S, Monlish D, Phamduy TB, Chrisey D, Cavanaugh JE, Flaherty P, Collins-Burow BM, Burow ME. Abstract 1052: Dual role of MEK1/2 and MEK5 in the reversal of epithelial-to-mesenchymal transition Cancer Research. 74: 1052-1052. DOI: 10.1158/1538-7445.Am2014-1052 |
0.732 |
|
| 2014 |
Burks HE, Rhodes L, Martin E, Phamduy T, Elliot S, Hoang V, Segar H, Buechlein A, Rusch D, Miller D, Baddoo M, Flemington E, Nephew K, Chrisey D, Collins-Burow B, et al. Abstract 1034: ZEB2 promotes cell motility and metastasis in ER+ breast cancer cells Cancer Research. 74: 1034-1034. DOI: 10.1158/1538-7445.Am2014-1034 |
0.731 |
|
| 2013 |
Strong AL, Strong TA, Rhodes LV, Semon JA, Zhang X, Shi Z, Zhang S, Gimble JM, Burow ME, Bunnell BA. Obesity associated alterations in the biology of adipose stem cells mediate enhanced tumorigenesis by estrogen dependent pathways. Breast Cancer Research : Bcr. 15: R102. PMID 24176089 DOI: 10.1186/Bcr3569 |
0.679 |
|
| 2013 |
Antoon JW, Martin EC, Lai R, Salvo VA, Tang Y, Nitzchke AM, Elliott S, Nam SY, Xiong W, Rhodes LV, Collins-Burow B, David O, Wang G, Shan B, Beckman BS, et al. MEK5/ERK5 signaling suppresses estrogen receptor expression and promotes hormone-independent tumorigenesis. Plos One. 8: e69291. PMID 23950888 DOI: 10.1371/Journal.Pone.0069291 |
0.76 |
|
| 2013 |
Miller DF, Yan PS, Buechlein A, Rodriguez BA, Yilmaz AS, Goel S, Lin H, Collins-Burow B, Rhodes LV, Braun C, Pradeep S, Rupaimoole R, Dalkilic M, Sood AK, Burow ME, et al. A new method for stranded whole transcriptome RNA-seq. Methods (San Diego, Calif.). 63: 126-34. PMID 23557989 DOI: 10.1016/J.Ymeth.2013.03.023 |
0.48 |
|
| 2013 |
Antoon JW, Nitzchke AM, Martin EC, Rhodes LV, Nam S, Wadsworth S, Salvo VA, Elliott S, Collins-Burow B, Nephew KP, Burow ME. Inhibition of p38 mitogen-activated protein kinase alters microRNA expression and reverses epithelial-to-mesenchymal transition. International Journal of Oncology. 42: 1139-50. PMID 23403951 DOI: 10.3892/Ijo.2013.1814 |
0.669 |
|
| 2013 |
Johnson KP, Yearby LA, Stoute D, Burow ME, Rhodes LV, Gray M, Carriere P, Tilghman SL, McLachlan JA, Ochieng J. In vitro and in vivo evaluation of novel anticancer agents in triple negative breast cancer models. Journal of Health Care For the Poor and Underserved. 24: 104-11. PMID 23395947 DOI: 10.1353/Hpu.2013.0047 |
0.707 |
|
| 2013 |
Tilghman SL, Rhodes LV, Bratton MR, Carriere P, Preyan LC, Boue SM, Vasaitis TS, McLachlan JA, Burow ME. Phytoalexins, miRNAs and breast cancer: a review of phytochemical-mediated miRNA regulation in breast cancer. Journal of Health Care For the Poor and Underserved. 24: 36-46. PMID 23395943 DOI: 10.1353/Hpu.2013.0036 |
0.669 |
|
| 2013 |
Phamduy TB, Rhodes LV, Burow ME, Chrisey DB. Abstract A016: Electrical impedance assessment of the effect of LBH589 on the cellular behavior and migratory potential of breast cancer cells Molecular Cancer Research. 11. DOI: 10.1158/1557-3125.Advbc-A016 |
0.656 |
|
| 2012 |
Martin EC, Bratton MR, Zhu Y, Rhodes LV, Tilghman SL, Collins-Burow BM, Burow ME. Insulin-like growth factor-1 signaling regulates miRNA expression in MCF-7 breast cancer cell line. Plos One. 7: e49067. PMID 23226206 DOI: 10.1371/Journal.Pone.0049067 |
0.688 |
|
| 2012 |
Antoon JW, Lai R, Struckhoff AP, Nitschke AM, Elliott S, Martin EC, Rhodes LV, Yoon NS, Salvo VA, Shan B, Beckman BS, Nephew KP, Burow ME. Altered death receptor signaling promotes epithelial-to-mesenchymal transition and acquired chemoresistance. Scientific Reports. 2: 539. PMID 22844580 DOI: 10.1038/Srep00539 |
0.68 |
|
| 2012 |
Rhodes LV, Tilghman SL, Boue SM, Wang S, Khalili H, Muir SE, Bratton MR, Zhang Q, Wang G, Burow ME, Collins-Burow BM. Glyceollins as novel targeted therapeutic for the treatment of triple-negative breast cancer. Oncology Letters. 3: 163-171. PMID 22740874 DOI: 10.3892/Ol.2011.460 |
0.739 |
|
| 2012 |
Tate CR, Rhodes LV, Segar HC, Driver JL, Pounder FN, Burow ME, Collins-Burow BM. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat. Breast Cancer Research : Bcr. 14: R79. PMID 22613095 DOI: 10.1186/Bcr3192 |
0.73 |
|
| 2012 |
Zhou C, Zhong Q, Rhodes LV, Townley I, Bratton MR, Zhang Q, Martin EC, Elliott S, Collins-Burow BM, Burow ME, Wang G. Proteomic analysis of acquired tamoxifen resistance in MCF-7 cells reveals expression signatures associated with enhanced migration. Breast Cancer Research : Bcr. 14: R45. PMID 22417809 DOI: 10.1186/Bcr3144 |
0.646 |
|
| 2012 |
Tilghman SL, Bratton MR, Segar HC, Martin EC, Rhodes LV, Li M, McLachlan JA, Wiese TE, Nephew KP, Burow ME. Endocrine disruptor regulation of microRNA expression in breast carcinoma cells. Plos One. 7: e32754. PMID 22403704 DOI: 10.1371/Journal.Pone.0032754 |
0.687 |
|
| 2012 |
Wood CE, Boue SM, Collins-Burow BM, Rhodes LV, Register TC, Cline JM, Dewi FN, Burow ME. Glyceollin-elicited soy protein consumption induces distinct transcriptional effects as compared to standard soy protein. Journal of Agricultural and Food Chemistry. 60: 81-6. PMID 22126086 DOI: 10.1021/Jf2034863 |
0.515 |
|
| 2012 |
Rhodes LV, Nitschke AM, Segar HC, Martin EC, Driver JL, Elliott S, Nam SY, Li M, Nephew KP, Burow ME, Collins-Burow BM. The histone deacetylase inhibitor trichostatin A alters microRNA expression profiles in apoptosis-resistant breast cancer cells. Oncology Reports. 27: 10-6. PMID 21971930 DOI: 10.3892/Or.2011.1488 |
0.687 |
|
| 2011 |
Rhodes LV, Bratton MR, Zhu Y, Tilghman SL, Muir SE, Salvo VA, Tate CR, Elliott S, Nephew KP, Collins-Burow BM, Burow ME. Effects of SDF-1-CXCR4 signaling on microRNA expression and tumorigenesis in estrogen receptor-alpha (ER-α)-positive breast cancer cells. Experimental Cell Research. 317: 2573-81. PMID 21906588 DOI: 10.1016/J.Yexcr.2011.08.016 |
0.764 |
|
| 2011 |
Antoon JW, Meacham WD, Bratton MR, Slaughter EM, Rhodes LV, Ashe HB, Wiese TE, Burow ME, Beckman BS. Pharmacological inhibition of sphingosine kinase isoforms alters estrogen receptor signaling in human breast cancer Journal of Molecular Endocrinology. 46: 205-216. PMID 21321095 DOI: 10.1530/Jme-10-0116 |
0.726 |
|
| 2011 |
Rhodes LV, Short SP, Neel NF, Salvo VA, Zhu Y, Elliott S, Wei Y, Yu D, Sun M, Muir SE, Fonseca JP, Bratton MR, Segar C, Tilghman SL, Sobolik-Delmaire T, et al. Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. Cancer Research. 71: 603-13. PMID 21123450 DOI: 10.1158/0008-5472.Can-10-3185 |
0.75 |
|
| 2010 |
Rhodes LV, Antoon JW, Muir SE, Elliott S, Beckman BS, Burow ME. Effects of human mesenchymal stem cells on ER-positive human breast carcinoma cells mediated through ER-SDF-1/CXCR4 crosstalk. Molecular Cancer. 9: 295. PMID 21087507 DOI: 10.1186/1476-4598-9-295 |
0.682 |
|
| 2010 |
Antoon JW, White MD, Meacham WD, Slaughter EM, Muir SE, Elliott S, Rhodes LV, Ashe HB, Wiese TE, Smith CD, Burow ME, Beckman BS. Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640. Endocrinology. 151: 5124-35. PMID 20861237 DOI: 10.1210/En.2010-0420 |
0.749 |
|
| 2010 |
Jiang Q, Payton-Stewart F, Elliott S, Driver J, Rhodes LV, Zhang Q, Zheng S, Bhatnagar D, Boue SM, Collins-Burow BM, Sridhar J, Stevens C, McLachlan JA, Wiese TE, Burow ME, et al. Effects of 7-O substitutions on estrogenic and anti-estrogenic activities of daidzein analogues in MCF-7 breast cancer cells. Journal of Medicinal Chemistry. 53: 6153-63. PMID 20669983 DOI: 10.1021/Jm100610W |
0.654 |
|
| 2010 |
Rhodes LV, Burow ME. Human mesenchymal stem cells as mediators of breast carcinoma tumorigenesis and progression. Thescientificworldjournal. 10: 1084-7. PMID 20563531 DOI: 10.1100/Tsw.2010.108 |
0.676 |
|
| 2010 |
Rhodes LV, Muir SE, Elliott S, Guillot LM, Antoon JW, Penfornis P, Tilghman SL, Salvo VA, Fonseca JP, Lacey MR, Beckman BS, McLachlan JA, Rowan BG, Pochampally R, Burow ME. Adult human mesenchymal stem cells enhance breast tumorigenesis and promote hormone independence. Breast Cancer Research and Treatment. 121: 293-300. PMID 19597705 DOI: 10.1007/S10549-009-0458-2 |
0.694 |
|
| 2010 |
Hawthorne T, Gallien J, Gibbs L, Jones J, Muir S, Rhodes LV, Driver J, Khalili H, Burow M, Parker-Johnson KA. Abstract 4606: An in vitro and in vivo evaluation of novel anticancer agents in a triple negative breast cancer model Endocrinology. 70: 4606-4606. DOI: 10.1158/1538-7445.Am10-4606 |
0.685 |
|
| 2009 |
Nierth-Simpson EN, Martin MM, Chiang TC, Melnik LI, Rhodes LV, Muir SE, Burow ME, McLachlan JA. Human uterine smooth muscle and leiomyoma cells differ in their rapid 17beta-estradiol signaling: implications for proliferation. Endocrinology. 150: 2436-45. PMID 19179429 DOI: 10.1210/En.2008-0224 |
0.579 |
|
| Show low-probability matches. |